{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:52:45Z","timestamp":1761515565751,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.4158\/ep.14.8.985","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T22:19:15Z","timestamp":1365200355000},"page":"985-992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of Spironolactone Therapy on Albuminuria in Patients with Type 2 Diabetes Treated with Angiotensin-Converting Enzyme Inhibitors"],"prefix":"10.1016","volume":"14","author":[{"given":"Michael B.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir H.","family":"Hamrahian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias S.","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.14.8.985_bb0005","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients","volume":"66","author":"Rossing","year":"2004","journal-title":"Kidney Int"},{"key":"10.4158\/EP.14.8.985_bb0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes","volume":"310","author":"Mogensen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.14.8.985_bb0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.4158\/EP.14.8.985_bb0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9149(97)00312-3","article-title":"Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group","volume":"80","author":"Agewall","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP.14.8.985_bb0025","first-page":"S10","article-title":"Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial","volume":"63","author":"Grimm","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.4158\/EP.14.8.985_bb0030","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0272-6386(99)70442-7","article-title":"Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation","volume":"33","author":"Keane","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.4158\/EP.14.8.985_bb0035","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diab.41.6.736","article-title":"Prospective study of microalbuminuria as predictor of mortality in NIDDM","volume":"41","author":"Mattock","year":"1992","journal-title":"Diabetes"},{"key":"10.4158\/EP.14.8.985_bb0040","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2337\/diacare.28.3.745","article-title":"Diabetic nephropathy","volume":"28","author":"Bloomgarden","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.14.8.985_bb0045","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.14.8.985_bb0050","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [erratum in N Engl J Med. 1993;330:152]","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.14.8.985_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"year":"1995","series-title":"Hypertension: Pathophysiology, Diagnosis, and Management","key":"10.4158\/EP.14.8.985_bb0060"},{"key":"10.4158\/EP.14.8.985_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0039-128X(94)00016-6","article-title":"Aldosterone (ALDO) increases transmembrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channels","volume":"60","author":"Kornel","year":"1995","journal-title":"Steroids"},{"key":"10.4158\/EP.14.8.985_bb0070","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/0024-3205(82)90441-6","article-title":"Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle","volume":"30","author":"Weber","year":"1982","journal-title":"Life Sci"},{"key":"10.4158\/EP.14.8.985_bb0075","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP.14.8.985_bb0080","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"10.4158\/EP.14.8.985_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.ki.5000438","article-title":"Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats","volume":"70","author":"Han","year":"2006","journal-title":"Kidney Int"},{"key":"10.4158\/EP.14.8.985_bb0090","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.4158\/EP.14.8.985_bb0095","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1210\/jc.2005-1718","article-title":"Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy","volume":"91","author":"Takebayashi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.14.8.985_bb0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.4158\/EP.14.8.985_bb0105","first-page":"230","article-title":"Aldosterone and PAI-1: implications for renal injury","volume":"15","author":"Brown","year":"2002","journal-title":"J Nephrol"},{"key":"10.4158\/EP.14.8.985_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.14.8.985_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP.14.8.985_bb0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.4158\/EP.14.8.985_bb0125","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.4158\/EP.14.8.985_bb0130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.4158\/EP.14.8.985_bb0135","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ncpneph0192","article-title":"Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy","volume":"2","author":"Epstein","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.4158\/EP.14.8.985_bb0140","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.14.8.985_bb0145","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE Inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.14.8.985_bb0150","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archinte.163.5.525","volume":"163","author":"Douglas","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP.14.8.985_bb0155","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"key":"10.4158\/EP.14.8.985_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0895-7061(03)01008-2","article-title":"Hypertension in women","volume":"17","author":"Safar","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.4158\/EP.14.8.985_bb0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-126-10-199705150-00002","article-title":"Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials","volume":"126","author":"Gueyffier","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP.14.8.985_bb0170","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.4158\/EP.14.8.985_bb0175","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"10.4158\/EP.14.8.985_bb0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2288-7-30","article-title":"The Hawthorne Effect: a randomised, controlled trial","volume":"7","author":"McCarney","year":"2007","journal-title":"BMC Med Res Methodol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20411917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20411917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/25576807634VJ5X1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:48:14Z","timestamp":1761515294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20411917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S1530891X20411917"],"URL":"https:\/\/doi.org\/10.4158\/ep.14.8.985","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Spironolactone Therapy on Albuminuria in Patients with Type 2 Diabetes Treated with Angiotensin-Converting Enzyme Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.14.8.985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}